Clinical Trials
32 trialsSTARTRK-2
Hoffmann-La Roche
NAUTIKA1
Genentech, Inc.
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
UmbrellaMAX
Hoffmann-La Roche
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
HORIZON 1
Hoffmann-La Roche
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
STARTRK-NG
Hoffmann-La Roche
B-FAST
Hoffmann-La Roche
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Hoffmann-La Roche
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
CUPISCO
Hoffmann-La Roche
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
MyTACTIC
Genentech, Inc.
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
ROSALINE
Jules Bordet Institute
SPRING
Peking University Shenzhen Hospital
PIKACHU
Hunan Province Tumor Hospital
FINPROVE
Helsinki University Central Hospital
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
IMPRESS-N
Oslo University Hospital
DRUP
The Netherlands Cancer Institute
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Hoosier Cancer Research Network
ROME
Fondazione per la Medicina Personalizzata
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
STARTRK-1
Hoffmann-La Roche
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
Genentech, Inc.
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Hoffmann-La Roche